|
Indications and Dosage
Oral
Hypertension Adult: As monotherapy or in combination with other antihypertensive agents: Initially, 5-10 mg once daily. May increase dose to 20 mg once daily, if needed. Dosage and treatment recommendations may vary among countries and individual products (refer to specific product guidelines).
|
|
Contraindications
Heart failure.
|
|
Special Precautions
Patient with severe aortic stenosis, hypertrophic cardiomyopathy, outflow tract obstruction. Avoid abrupt withdrawal. Severe hepatic impairment. Elderly.
|
|
Adverse Reactions
Significant: Angina, MI, reflex tachycardia; peripheral oedema (dose dependent). Rarely, symptomatic hypotension (with or without syncope).
Blood and lymphatic system disorders: Thrombocytopenia. Cardiac disorders: AV block, extrasystoles. Eye disorders: Dry eye syndrome, eye pain. Gastrointestinal disorders: Gingival hyperplasia, nausea, vomiting, diarrhoea, heartburn, abdominal pain, abdominal distention, stomach discomfort, constipation, epigastric distress. General disorders and administration site conditions: Lethargy, malaise, shivering. Hepatobiliary disorders: Jaundice. Investigations: Abnormal creatine kinase levels, ECG abnormality, abnormal LFTs. Nervous system disorders: Headache, dizziness. Psychiatric disorders: Insomnia, amnesia. Renal and urinary disorders: Proteinuria, urinary frequency, urine sedimentation abnormality. Skin and subcutaneous tissue disorders: Rash, pruritus, rubor, photosensitivity. Vascular disorders: Hyperaemia, facial flushing. |
|
Patient Counseling Information
This drug may cause dizziness and syncope, if affected, do not drive or operate machinery.
|
|
Monitoring Parameters
Monitor blood pressure and heart rate. Assess for signs of peripheral oedema.
|
|
Overdosage
Symptoms: Dizziness, nausea, slurred speech, confusion, irregular heartbeat, difficulty in breathing. Management: Symptomatic treatment.
|
|
Drug Interactions
Enhanced therapeutic effect with cimetidine and azole antifungal agents (e.g. miconazole, itraconazole).
|
|
Food Interaction
Increased therapeutic effect with grapefruit juice.
|
|
Lab Interference
May cause falsely elevated spectrophotometric values of urinary vanillylmandelic acid. May cause a false-negative aldosterone/renin ratio (ARR).
|
|
Action
Description:
Mechanism of Action: Cilnidipine is a dihydropyridine Ca channel blocker. It inhibits Ca influx from L-type voltage-gated Ca channels in vascular smooth muscles thereby causing a decrease in peripheral vascular resistance and blood pressure. Additionally, it blocks the release of norepinephrine from sympathetic nerve endings through the inhibition of Ca influx from N-type voltage-gated Ca channels in sympathetic nerve endings, thus preventing the increase in heart rate during blood pressure-lowering events. Pharmacokinetics: Absorption: Absorbed from the small intestine. Time to peak plasma concentration: 1.8-2.2 hours. Metabolism: Metabolised in the liver by the CYP3A4 and partially by the CYP2C19 isoenzymes. Excretion: Via faeces (80%); urine (20%). Elimination half-life: 7.5 hours. |
|
Chemical Structure
 Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 5282138, Cilnidipine. https://pubchem.ncbi.nlm.nih.gov/compound/Cilnidipine. Accessed Oct. 24, 2023. |
|
Storage
Store below 30°C.
|
|
MIMS Class
|
|
ATC Classification
C08CA14 - cilnidipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
|
|
References
Anon. Cilnidipine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/07/2023. Buckingham R (ed). Cilnidipine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/07/2023. Cildine (Ajanta Pharma Phil). MIMS Philippines. http://www.mims.com/philippines. Accessed 04/07/2023.
|
Sign Out
